# IDUA

## Overview
The IDUA gene encodes the enzyme alpha-L-iduronidase, a lysosomal glycoside hydrolase that plays a pivotal role in the degradation of glycosaminoglycans (GAGs), specifically dermatan sulfate and heparan sulfate. This enzyme is essential for the removal of nonreducing terminal alpha-L-iduronic acid residues, facilitating the breakdown and recycling of GAGs within lysosomes (Scott1995Molecular; Yogalingam2004Identification). Alpha-L-iduronidase is characterized by a (β/α)8 barrel structure, typical of enzymes with a retaining mechanism, and undergoes post-translational modifications, including glycosylation, which are crucial for its function and stability (Brooks2001Glycosidase; Pierce2017Nglycan). Mutations in the IDUA gene can lead to mucopolysaccharidosis type I (MPS I), a lysosomal storage disorder marked by the accumulation of partially degraded GAGs, resulting in a spectrum of clinical manifestations ranging from mild to severe (Bertola2011IDUA; Ghosh2017IDUA).

## Structure
The human alpha-L-iduronidase (IDUA) enzyme is synthesized as a 653-amino-acid polypeptide and undergoes post-translational modifications, including glycosylation at six N-linked sites, which are crucial for its function and stability (Brooks2001Glycosidase; Pierce2017Nglycan). The enzyme is part of the glycoside hydrolase family, specifically clan GH-A, and is characterized by a (β/α)8 barrel 3D structure, which is common among enzymes with a retaining mechanism (Brooks2001Glycosidase). The critical catalytic residues, Glu182 and Glu299, are located at the C-terminal end of strands β4 and β7, respectively, and are essential for the enzyme's catalytic activity (Brooks2001Glycosidase).

The IDUA enzyme undergoes extensive proteolytic processing to produce multiple polypeptides, which is thought to occur intracellularly (Brooks2001Glycosidase). The presence of mannose-6-phosphate tags at certain glycosylation sites is important for lysosomal targeting (Pierce2017Nglycan). Although the 3D structure of IDUA has not been fully elucidated, homology models have been created using the crystal structure of β-D-xylosidase as a template, providing insights into its structural features (Kang2009Structural). The enzyme's structure is crucial for its role in the degradation of glycosaminoglycans, and mutations affecting its structure can lead to mucopolysaccharidosis type I (MPS I) (Bertola2011IDUA).

## Function
The IDUA gene encodes the enzyme alpha-L-iduronidase, which plays a crucial role in the lysosomal degradation of glycosaminoglycans (GAGs), specifically dermatan sulfate and heparan sulfate. In healthy human cells, alpha-L-iduronidase facilitates the removal of nonreducing terminal alpha-L-iduronic acid residues from these GAGs, a necessary step in their breakdown (Scott1995Molecular; Yogalingam2004Identification). This enzymatic activity prevents the accumulation of undegraded substrates within lysosomes, which is essential for maintaining normal cellular and tissue function (Zahoor2019Mapping; Ghosh2017IDUA).

Alpha-L-iduronidase is active within the lysosomes, where it ensures the proper turnover and recycling of GAGs, preventing their buildup that can lead to cellular and tissue pathology (Tippin2011Biochemical; Unger1994Recombinant). The enzyme's function is critical for cellular waste management and is particularly important for normal skeletal and connective tissue development (Clements1989Immunopurification). Deficiency in alpha-L-iduronidase activity, due to mutations in the IDUA gene, results in mucopolysaccharidosis type I (MPS I), a lysosomal storage disorder characterized by the accumulation of partially degraded GAGs (Scott1995Molecular; Yogalingam2004Identification).

## Clinical Significance
Mutations in the IDUA gene lead to mucopolysaccharidosis type I (MPS I), a lysosomal storage disorder characterized by a deficiency of the enzyme alpha-L-iduronidase. This enzyme deficiency results in the accumulation of glycosaminoglycans (GAGs) such as heparan sulfate and dermatan sulfate in lysosomes, causing a range of clinical manifestations (Scott1995Molecular; Ghosh2017IDUA). MPS I is clinically divided into three phenotypes based on severity: Hurler syndrome (severe), Hurler-Scheie syndrome (intermediate), and Scheie syndrome (mild) (Voskoboeva2022Mucopolysaccharidosis; Jahic2019“Missing).

The severe form, Hurler syndrome, is associated with early onset symptoms such as developmental delay, cognitive decline, and systemic complications (Ghosh2017IDUA). Common mutations like Q70X and W402X are frequently observed in patients with Hurler syndrome, leading to severe clinical outcomes (Bunge1995Mucopolysaccharidosis; Scott1992αLiduronidase). The presence of nonsense mutations is often linked to the severe phenotype, while milder forms may result from at least one mild allele (Vazna2009Mucopolysaccharidosis).

Treatment options for MPS I include enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT), with HSCT being preferred for severe cases to preserve cognitive function (Ghosh2017IDUA; Voskoboeva2022Mucopolysaccharidosis). Early diagnosis through newborn screening is emphasized to improve treatment outcomes (Ghosh2017IDUA).


## References


[1. (Vazna2009Mucopolysaccharidosis) Alzbeta Vazna, Clare Beesley, Linda Berna, Larisa Stolnaja, Helena Myskova, Michaela Bouckova, Hana Vlaskova, Helena Poupetova, Jiri Zeman, Martin Magner, Anna Hlavata, Bryan Winchester, Martin Hrebicek, and Lenka Dvorakova. Mucopolysaccharidosis type i in 21 czech and slovak patients: mutation analysis suggests a functional importance of c‐terminus of the idua protein. American Journal of Medical Genetics Part A, 149A(5):965–974, April 2009. URL: http://dx.doi.org/10.1002/ajmg.a.32812, doi:10.1002/ajmg.a.32812. This article has 26 citations.](https://doi.org/10.1002/ajmg.a.32812)

[2. (Yogalingam2004Identification) G. Yogalingam, X.-H. Guo, V.J. Muller, D.A. Brooks, P.R. Clements, E.D. Kakkis, and J.J. Hopwood. Identification and molecular characterization of α-l-iduronidase mutations present in mucopolysaccharidosis type i patients undergoing enzyme replacement therapy. Human Mutation, 24(3):199–207, September 2004. URL: http://dx.doi.org/10.1002/humu.20081, doi:10.1002/humu.20081. This article has 44 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.20081)

[3. (Ghosh2017IDUA) Arunabha Ghosh, Jean Mercer, Sabrina Mackinnon, Wyatt W Yue, Heather Church, Clare E Beesley, Alex Broomfield, Simon A Jones, and Karen Tylee. Idua mutational profile and genotype–phenotype relationships in uk patients with mucopolysaccharidosis type i. Human Mutation, 38(11):1555–1568, August 2017. URL: http://dx.doi.org/10.1002/humu.23301, doi:10.1002/humu.23301. This article has 17 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.23301)

[4. (Kang2009Structural) Tse Siang Kang and Raymond C. Stevens. Structural aspects of therapeutic enzymes to treat metabolic disorders. Human Mutation, 30(12):1591–1610, December 2009. URL: http://dx.doi.org/10.1002/humu.21111, doi:10.1002/humu.21111. This article has 26 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.21111)

[5. (Jahic2019“Missing) Amir Jahic, Sven Günther, Nicole Muschol, Barbro Fossøy Stadheim, Øivind Braaten, Hanne Kjensli Hyldebrandt, Gé‐Ann Kuiper, Karen Tylee, Frits A. Wijburg, and Christian Beetz. “missing mutations” in <scp>mps</scp> i: identification of two novel copy number variations by an <scp>idua</scp>‐specific in house <scp>mlpa</scp> assay. Molecular Genetics &amp; Genomic Medicine, July 2019. URL: http://dx.doi.org/10.1002/mgg3.615, doi:10.1002/mgg3.615. This article has 3 citations.](https://doi.org/10.1002/mgg3.615)

[6. (Brooks2001Glycosidase) D. A. Brooks, S. Fabrega, L. K. Hein, E. J. Parkinson, P. Durand, G. Yogalingam, U. Matte, R. Giugliani, A. Dasvarma, J. Eslahpazire, B. Henrissat, J.-P. Mornon, J. J. Hopwood, and P. Lehn. Glycosidase active site mutations in human -l-iduronidase. Glycobiology, 11(9):741–750, September 2001. URL: http://dx.doi.org/10.1093/glycob/11.9.741, doi:10.1093/glycob/11.9.741. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.1093/glycob/11.9.741)

[7. (Clements1989Immunopurification) P R Clements, D A Brooks, P A G McCourt, and J J Hopwood. Immunopurification and characterization of human α-<scp>l</scp>-iduronidase with the use of monoclonal antibodies. Biochemical Journal, 259(1):199–208, April 1989. URL: http://dx.doi.org/10.1042/bj2590199, doi:10.1042/bj2590199. This article has 30 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1042/bj2590199)

[8. (Zahoor2019Mapping) Muhammad Yasir Zahoor, Huma Arshad Cheema, Sadaqat Ijaz, Muhammad Nadeem Anjum, Khushnooda Ramzan, and Munir Ahmad Bhinder. Mapping of idua gene variants in pakistani patients with mucopolysaccharidosis type 1. Journal of Pediatric Endocrinology and Metabolism, 32(11):1221–1227, September 2019. URL: http://dx.doi.org/10.1515/jpem-2019-0188, doi:10.1515/jpem-2019-0188. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.1515/jpem-2019-0188)

[9. (Scott1992αLiduronidase) Hamish S. Scott, Tom Litjens, Paul V. Nelson, Doug A. Brooks, John J. Hopwood, and C. Phillip Morris. Α-l-iduronidase mutations (q70x and p533r) associate with a severe hurler phenotype. Human Mutation, 1(4):333–339, 1992. URL: http://dx.doi.org/10.1002/humu.1380010412, doi:10.1002/humu.1380010412. This article has 65 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.1380010412)

[10. (Voskoboeva2022Mucopolysaccharidosis) E. Yu Voskoboeva, T. M. Bookina, A. N. Semyachkina, S. V. Mikhaylova, N. D. Vashakmadze, G. V. Baydakova, E. Yu Zakharova, and S. I. Kutsev. Mucopolysaccharidosis type i in the russian federation and other republics of the former soviet union: molecular genetic analysis and epidemiology. Frontiers in Molecular Biosciences, January 2022. URL: http://dx.doi.org/10.3389/fmolb.2021.783644, doi:10.3389/fmolb.2021.783644. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fmolb.2021.783644)

[11. (Pierce2017Nglycan) Owen M. Pierce, Grant R. McNair, Xu He, Hiroyuki Kajiura, Kazuhito Fujiyama, and Allison R. Kermode. N-glycan structures and downstream mannose-phosphorylation of plant recombinant human alpha-l-iduronidase: toward development of enzyme replacement therapy for mucopolysaccharidosis i. Plant Molecular Biology, 95(6):593–606, November 2017. URL: http://dx.doi.org/10.1007/s11103-017-0673-x, doi:10.1007/s11103-017-0673-x. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s11103-017-0673-x)

[12. (Tippin2011Biochemical) Brigette L. Tippin, Larisa Troitskaya, Shih‐hsin Kan, Amanda K. Todd, Steven Q. Le, and Patricia I. Dickson. Biochemical characterization of fluorescent‐labeled recombinant human alpha‐<scp>l</scp>‐iduronidase in vitro. Biotechnology and Applied Biochemistry, 58(6):391–396, October 2011. URL: http://dx.doi.org/10.1002/bab.52, doi:10.1002/bab.52. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/bab.52)

[13. (Bunge1995Mucopolysaccharidosis) Susanna Bunge, Wim J. Kleijer, Cordula Steglich, Michael Beck, Eberhard Schwinger, and Andreas Gal. Mucopolysaccharidosis type i: identification of 13 novel mutations of the α-l-iduronidase gene. Human Mutation, 6(1):91–94, 1995. URL: http://dx.doi.org/10.1002/humu.1380060119, doi:10.1002/humu.1380060119. This article has 35 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.1380060119)

[14. (Scott1995Molecular) Hamish S. Scott, Susanna Bunge, Andreas Gal, Lome A. Clarke, C. Phillip Morris, and John J. Hopwood. Molecular genetics of muccpolysaccharidosis type i: diagnostic, clinical, and biological implications. Human Mutation, 6(4):288–302, 1995. URL: http://dx.doi.org/10.1002/humu.1380060403, doi:10.1002/humu.1380060403. This article has 156 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.1380060403)

[15. (Bertola2011IDUA) Francesca Bertola, Mirella Filocamo, Giorgio Casati, Matthew Mort, Camillo Rosano, Anna Tylki-Szymanska, Beyhan Tüysüz, Orazio Gabrielli, Serena Grossi, Maurizio Scarpa, Giancarlo Parenti, Daniela Antuzzi, Jaime Dalmau, Maja Di Rocco, Carlo Dionisi Vici, Ilyas Okur, Jordi Rosell, Attilio Rovelli, Francesca Furlan, Miriam Rigoldi, Andrea Biondi, David N Cooper, and Rossella Parini. Idua mutational profiling of a cohort of 102 european patients with mucopolysaccharidosis type i: identification and characterization of 35 novel α-l-iduronidase (idua) alleles. Human Mutation, 32(6):E2189–E2210, March 2011. URL: http://dx.doi.org/10.1002/humu.21479, doi:10.1002/humu.21479. This article has 61 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.21479)

[16. (Unger1994Recombinant) E G Unger, J Durrant, D S Anson, and J J Hopwood. Recombinant α-<scp>l</scp>-iduronidase: characterization of the purified enzyme and correction of mucopolysaccharidosis type i fibroblasts. Biochemical Journal, 304(1):43–49, November 1994. URL: http://dx.doi.org/10.1042/bj3040043, doi:10.1042/bj3040043. This article has 44 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1042/bj3040043)